valcyte 50 mg/ml pulver til oral opløsning
cheplapharm arzneimittel gmbh - valganciclovirhydrochlorid - pulver til oral opløsning - 50 mg/ml
valganciclovir "accord" 450 mg filmovertrukne tabletter
accord healthcare b.v. - valganciclovirhydrochlorid - filmovertrukne tabletter - 450 mg
valganciclovir "orion" 450 mg filmovertrukne tabletter
aurobindo pharma (malta) limited - valganciclovirhydrochlorid - filmovertrukne tabletter - 450 mg
valganciclovir "sandoz" 450 mg filmovertrukne tabletter
sandoz a/s - valganciclovirhydrochlorid - filmovertrukne tabletter - 450 mg
valganciclovir "teva" 450 mg filmovertrukne tabletter
teva b.v. - valganciclovirhydrochlorid - filmovertrukne tabletter - 450 mg
valganciclovir "medical valley" 450 mg filmovertrukne tabletter
medical valley invest ab - valganciclovirhydrochlorid - filmovertrukne tabletter - 450 mg
ganciclovir "oresund pharma" 500 mg pulver til koncentrat til infusionsvæske, opløsning
Øresund pharma aps - ganciclovirnatrium - pulver til koncentrat til infusionsvæske, opløsning - 500 mg
cytarabin "actavis" 100 mg/ml injektions-/infusionsvæske, opløsning
actavis group ptc ehf. - cytarabin - injektions-/infusionsvæske, opløsning - 100 mg/ml
amphocil 50 mg pulver til infusionsvæske, opløsning
alkopharma sarl - amphotericin b - pulver til infusionsvæske, opløsning - 50 mg
cancidas (previously caspofungin msd)
merck sharp & dohme b.v. - caspofungin (as acetate) - candidiasis; aspergillosis - antimykotika til systemisk brug - treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and / or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.